Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors
Pediatric Blood & Cancer · 2024-12 · 71 (12)
DOI: 10.1002/pbc.31340 ↗At a glance
Fallbericht in Pediatric Blood & Cancer, published online on 2024-09-27. Written by Shu-Yi Guo and 6 co-authors. Institution: Department of Hematology/Oncology, Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Immune Checkpoint Inhibitors. Cited 5 times so far (Crossref); 23 references. Funded by: Basic Research Project (Dengfeng Hospital) jointly funded by Universities (Institutes) in Guangzhou, Sun Yat-sen Pilot Scientific Research Fund, Guangdong Basic and Applied Basic Research Foundation.
Abstract (original language)
Purpose
Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is a type of pediatric HLH that occurs frequently in Asia. Although immunochemotherapy based on etoposide and hormone has improved survival rates, there are still about 30% of HLH patients that do not respond. The objective of the article is to examine the efficacy and safety of programmed cell death protein 1 (PD‐1) inhibitors for children with relapsed/refractory (r/r) EBV‐HLH.
Methods
A retrospective case note review of four pediatric patients with r/r EBV‐HLH who were treated with PD‐1 inhibitors at Sun Yat‐sen Memorial Hospital, Sun Yat‐sen University.
Results
All four patients responded to PD‐1 inhibitors and achieved partial response after their first infusion. Plasma EBV DNA copy number and HLH‐related monitoring indicators decreased in all of these patients. All patients received allogeneic hematopoietic stem cell transplantation (allo‐HSCT), and two were still alive at the last follow‐up on December 30, 2022. Two patients died because of transplantation‐related complications. Serious side effects included increased liver enzymes and edema in two patients.
Conclusion
PD‐1 inhibitors are an effective salvage therapy and can provide a bridge to allo‐HSCT for pediatric patients with r/r EBV‐HLH. However, side effects should be monitered.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology/Oncology, Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
ORCID profiles: Jia-Ying Lei, Kun-Yin Qiu, Dun-Hua Zhou
Funding
- Basic Research Project (Dengfeng Hospital) jointly funded by Universities (Institutes) in Guangzhou
- Sun Yat-sen Pilot Scientific Research Fund
- Guangdong Basic and Applied Basic Research Foundation
- Special topic of science and technology for agriculture and social development of Guangzhou key R & D plan
- Bethune Medical Scientific Research Fund Project
- Guangdong Medical Scientific Research Foundation
- Guangzhou Basic and Applied Basic Research Foundation
- Yat-sen Excellent Young Scientists Fund
Cite
APA
Guo, S. Y., Wang, J., Fang, J. P., Lei, J. Y., Wu, X. Q., Qiu, K. Y., & Zhou, D. H. (2024). Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors. Pediatric Blood & Cancer, 71(12). https://doi.org/10.1002/pbc.31340
Vancouver
Guo SY, Wang J, Fang JP, Lei JY, Wu XQ, Qiu KY, et al. Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors. Pediatric Blood & Cancer. 2024;71(12). doi:10.1002/pbc.31340
BibTeX
@article{Guo2024,
author = {Guo, Shu-Yi and Wang, Jian and Fang, Jian-Pei and Lei, Jia-Ying and Wu, Xiao-Qin and Qiu, Kun-Yin and Zhou, Dun-Hua},
title = {Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors},
journal = {Pediatric Blood & Cancer},
year = {2024},
volume = {71},
number = {12},
doi = {10.1002/pbc.31340}
}
EUVIMED